Stay updated with breaking news from Mark Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target raised by Mizuho from $66.00 to $74.00 in a research note released on Wednesday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock. ITCI has been the topic of a number of other research reports. Needham & Company LLC restated […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its target price increased by Canaccord Genuity Group from $93.00 to $98.00 in a report published on Wednesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also weighed in on ITCI. Needham & Company […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target upped by Bank of America from $62.00 to $63.00 in a research report released on Wednesday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald restated an overweight […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Mark Neumann sold 15,604 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $54.31, for a total value of $847,453.24. Following the sale, the executive vice president now directly owns 45,339 shares of the company’s […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) was down 2.7% on Friday after an insider sold shares in the company. The company traded as low as $54.26 and last traded at $54.56. Approximately 279,286 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 754,600 shares. The stock had […]